Related Experiment Video

Updated: Jun 8, 2026

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin
08:57

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Published on: March 26, 2015

Emerging oral treatments in multiple sclerosis - clinical utility of cladribine tablets

Claudio Gasperini1, Serena Ruggieri, Carlo Pozzilli

  • 1Department of Neurosciences, S Camillo Forlanini Hospital, Rome, Italy;

Therapeutics and Clinical Risk Management
|September 22, 2010
PubMed

Insights

New oral therapies for multiple sclerosis (MS) are emerging, offering improved adherence and efficacy. Cladribine, an oral immunosuppressant, shows promise for short-course dosing and sustained immune regulation in MS treatment.

Area of Science:

  • Neuroimmunology
  • Pharmacology

Background:

  • Multiple sclerosis (MS) is a leading cause of neurological disability in young adults, driven by an autoimmune central nervous system (CNS) disorder.
  • Current disease-modifying drugs (DMDs) for MS often involve frequent parenteral administration, leading to suboptimal adherence and efficacy.
  • There is a critical need for novel therapeutic strategies with improved patient compliance and clinical outcomes.

Purpose of the Study:

  • To review emerging oral therapies for multiple sclerosis (MS).
  • To present data on the clinical use of cladribine in MS.
  • To discuss future perspectives for cladribine in MS management.

Main Methods:

  • Review of existing literature on oral MS therapies.
  • Analysis of clinical data regarding cladribine's efficacy and safety profile.
  • Exploration of cladribine's mechanism of action as an immunosuppressant.

Main Results:

  • Several oral therapies are under development for MS, including fingolimod, fumaric acid, teriflunomide, and laquinimod.
  • Cladribine is a unique oral therapy with potential for short-course dosing, offering sustained immune regulation via lymphocyte depletion.
  • Cladribine possesses a well-established safety profile, supported by over 15 years of use in oncology and MS.

Conclusions:

  • Oral therapies represent a significant advancement in MS treatment, addressing limitations of current parenteral DMDs.
  • Cladribine's distinct short-course dosing and safety profile position it as a promising therapeutic option for MS.
  • Further research and clinical application of cladribine may offer improved long-term management for MS patients.
Keywords:
cladribinedisease modifying drugsmultiple sclerosisoral therapytreatment adherence

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...